Niagen Bioscience wins FDA rare pediatric disease designation for NB4168 in ataxia telangiectasia

Niagen Bioscience, Inc.

Niagen Bioscience, Inc.

NAGE

0.00
  • Niagen Bioscience won FDA Rare Pediatric Disease designation for NB4168 to treat ataxia-telangiectasia.
  • EMA granted orphan medicinal product designation for NB4168, supporting global clinical development incentives for the rare genetic disorder.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713674314) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.